English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

A rapidly growing number of new recombinant human colony-stimulating factors (CSFs) are entering various phases ofclinical testing. With the recent approval of granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophagecolony-stimulating factor (GM-CSF) for clinical use, newer CSFs will be developed for awidening spectrum of disease states singularly and in combination with other CSFs. Interleukin (IL)-3 is being tested in early clinical trials, and combination studies with G-CSF and GM-CSF are to follow soon.lL-6 presently is in animal model testing, but already shows promise of amplifying the restorativecapabilities of IL-3. IL-4 , GM-CSF and others. As a single agent, IL-6 may be instrumental in clarifyingdisease processes and therapeutics in diseases ranging from multiple myeloma to glomerulonephritis.Agents such as WR-2721 which appear to protect early progenitors with or without proliferative effectslikely will add another dimension to the therapeutic alternatives for restoring aberrant myelopoiesis. Therange of potential clinical application for new CSFs rapidly is expanding beyond oncology to include diseaseswhere infection prevention or therapy against established infection is the prime target of treatment

Potential Manipulations to Restore Aberrant Myelopoiesis: The Role of New Colony-Stimulating Factors and other Agents